rpl-19 Antibody

What is RPL19 and what is its primary biological function?

RPL19 (Ribosomal Protein L19) functions as a component of the large ribosomal subunit (60S). It is integral to the ribosome, which is a large ribonucleoprotein complex responsible for protein synthesis in the cell. RPL19 contributes to the structural and functional integrity of the ribosome, ultimately facilitating its role in translating mRNA into proteins . Beyond its canonical function in translation, emerging research suggests RPL19 may have extraribosomal functions, particularly in contexts of disease progression and immune regulation as evidenced by its involvement in pathways related to cancer progression and inflammatory responses .

What applications is the RPL19 antibody suitable for in laboratory research?

The RPL19 antibody demonstrates versatility across multiple research applications. Current validated applications include:

• Western Blot (WB): For detection of RPL19 protein in cell and tissue lysates

• Immunohistochemistry on paraffin-embedded sections (IHC-P): For examining RPL19 expression patterns in tissue samples

• Immunocytochemistry/Immunofluorescence (ICC/IF): For visualizing RPL19 localization within cells

Researchers should note that while these applications have been validated primarily in human and mouse samples, applications to other species may be possible based on sequence homology, though such cross-reactivity should be experimentally verified before proceeding with critical experiments .

How is RPL19 antibody specificity validated in experimental contexts?

Validation of RPL19 antibody specificity typically involves multiple complementary approaches:

• Western blot analysis using known RPL19-expressing cell lines (e.g., HeLa, MCF-7, and 293 cell lysates) to confirm detection of a band at the expected molecular weight

• Immunofluorescence studies in established cell lines with known RPL19 expression patterns

• Immunohistochemical analysis of tissues with established RPL19 expression profiles

• Inclusion of appropriate negative controls (e.g., secondary antibody only, isotype controls)

• Where possible, validation through additional techniques such as mass spectrometry or genetic knockdown/knockout experiments to confirm antibody specificity

Researchers should always include appropriate positive and negative controls when using RPL19 antibodies to ensure reliable and reproducible results.

How does RPL19 expression correlate with disease progression in cancer research models?

Mechanistically, gene enrichment analysis reveals that high RPL19 expression correlates with upregulation of cell cycle pathways and downregulation of bile acid metabolism pathways, suggesting that RPL19 may influence HCC progression through these mechanisms . Furthermore, immune infiltration analysis indicates that elevated RPL19 expression is associated with suppressed immune responses, potentially contributing to tumor immune evasion .

These findings suggest that RPL19 antibody-based detection methods could serve as valuable tools for risk stratification and treatment planning in oncology research.

What role does RPL19 play in immune regulation during infectious disease processes?

Recent research has uncovered a potentially significant role for RPL19 in immune regulation during infectious disease processes, particularly in spinal tuberculosis (STB). Bioinformatic analyses have identified RPL19 as one of nine key COVID-19-related proteins involved in the regulatory mechanisms of STB .

The relationship between RPL19 and immune function appears to be inhibitory in nature. Studies have demonstrated a negative correlation between RPL19 expression and the immune gene CD14 . Similarly, RPL19 shows a negative correlation with B cells naive populations in STB tissue samples . This suggests that RPL19 might suppress B cell naive populations in STB by regulating CD14 expression, potentially contributing to immune dysregulation during infection.

This emerging understanding of RPL19's immunomodulatory functions offers new perspectives for researchers investigating host-pathogen interactions and may present novel therapeutic targets for infectious disease intervention.

What technical considerations should be addressed when using RPL19 antibody for quantitative protein expression analysis?

When employing RPL19 antibody for quantitative protein expression analysis, researchers should consider several technical factors to ensure reliable and reproducible results:

• Antibody validation: Confirm specificity through positive and negative controls specific to your experimental system.

• Sample preparation standardization:

  • For Western blotting: Standardize protein extraction methods, quantification techniques, and loading controls

  • For IHC/ICC: Optimize fixation protocols, antigen retrieval methods, and blocking procedures

• Signal normalization strategies: When analyzing RPL19 expression levels quantitatively, normalize against appropriate housekeeping proteins or total protein staining methods.

• Detection system linearity: Ensure your detection system (chemiluminescence, fluorescence) operates within the linear range for accurate quantification.

• Cross-platform validation: Confirm expression patterns using complementary techniques (e.g., validate Western blot findings with immunofluorescence).

• Statistical analysis: Apply appropriate statistical methods for comparing RPL19 expression between experimental groups, considering biological and technical replicates.

For subcellular localization studies, carefully optimize permeabilization conditions, as RPL19's ribosomal localization may require specific permeabilization protocols for accurate visualization.

What are the optimal protocols for RPL19 detection in different experimental systems?

Based on validated applications, here are optimized protocols for RPL19 detection across different experimental systems:

Western Blot Protocol:

• Sample preparation: Lyse cells/tissues in RIPA buffer with protease inhibitors

• Protein quantification: Bradford or BCA assay

• SDS-PAGE: Load 20-30 μg protein per lane

• Transfer: Standard wet transfer to PVDF membrane

• Blocking: 5% non-fat milk in TBST for 1 hour at room temperature

• Primary antibody: Dilute RPL19 antibody at 1/500 in blocking solution, incubate overnight at 4°C

• Washing: 3 × 10 minutes with TBST

• Secondary antibody: HRP-conjugated anti-rabbit IgG (1:5000) for 1 hour at room temperature

• Detection: ECL substrate visualization

Immunofluorescence Protocol:

• Cell preparation: Grow cells on coverslips to 70-80% confluence

• Fixation: 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilization: 0.1% Triton X-100 for 10 minutes

• Blocking: 1% BSA, 10% normal goat serum in PBS for 1 hour

• Primary antibody: Dilute RPL19 antibody at 1/100 in blocking solution, incubate overnight at 4°C

• Washing: 3 × 5 minutes with PBS

• Secondary antibody: Alexa Fluor 488-conjugated goat anti-rabbit IgG (1:1000) for 1 hour at room temperature

• Counterstain: DAPI for nuclear visualization

• Mounting and imaging: Mount with anti-fade medium and visualize using confocal microscopy

Immunohistochemistry Protocol:

• Tissue preparation: Formalin-fixed, paraffin-embedded sections (4-6 μm)

• Deparaffinization and rehydration: Standard xylene and ethanol series

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

• Endogenous peroxidase blocking: 3% H₂O₂ for 10 minutes

• Protein blocking: 5% normal goat serum for 1 hour

• Primary antibody: Dilute RPL19 antibody at 1/100 in blocking solution, incubate overnight at 4°C

• Washing: 3 × 5 minutes with PBS

• Secondary antibody: HRP-polymer detection system for 30 minutes

• Visualization: DAB chromogen development

• Counterstaining: Hematoxylin for nuclear visualization

• Dehydration and mounting: Standard ethanol series, xylene, and mounting medium

How can researchers effectively use RPL19 antibody in multiplexing experiments?

Multiplexing with RPL19 antibody requires careful consideration of several technical factors:

For Fluorescent Multiplexing in IF/IHC:

• Antibody compatibility: Select primary antibodies raised in different host species to avoid cross-reactivity

• Spectral separation: Choose fluorophores with minimal spectral overlap

• Sequential detection: For antibodies from the same host species, consider sequential staining with intermediate blocking steps

• Controls: Include single-stained controls to verify specificity and absence of bleed-through

For Multiparameter Analysis in Flow Cytometry:

• Panel design: Consider expression levels of targets when selecting fluorophores

• Compensation: Perform proper compensation using single-stained controls

• Permeabilization optimization: Since RPL19 is primarily intracellular, optimize permeabilization conditions that maintain detection of both surface and intracellular markers

For Multiplex Western Blotting:

• Size separation: Ensure adequate separation between RPL19 (approximately 23 kDa) and other proteins of interest

• Stripping considerations: If re-probing membranes, validate that stripping protocols do not significantly reduce RPL19 signal

• Dual-color detection systems: Consider using systems that allow simultaneous detection of multiple proteins

Example Multiplex Panel for Studying RPL19 in Immune Context:

• RPL19 (rabbit polyclonal) with Alexa Fluor 488 secondary

• CD14 (mouse monoclonal) with Alexa Fluor 594 secondary

• DAPI for nuclear counterstain

This combination would allow simultaneous visualization of RPL19 expression, CD14 (relevant based on the correlation identified in STB research ), and nuclear morphology.

How does RPL19 expression contribute to immune dysregulation in infectious diseases?

RPL19 appears to play a significant role in immune dysregulation during infectious diseases, particularly in spinal tuberculosis (STB). Analysis of STB tissue samples has revealed important correlations between RPL19 and immune components:

• Negative regulation of CD14: RPL19 shows a negative correlation with CD14, a critical immune gene involved in pathogen recognition and inflammatory response . This suggests that increased RPL19 expression may suppress CD14-mediated immune pathways during infection.

• Suppression of B cell populations: Data indicates a negative correlation between RPL19 expression and B cells naive populations in STB tissue . This relationship implies that RPL19 might inhibit B cell development or activation, potentially compromising adaptive immune responses against pathogens.

• Pathway integration in COVID-19 context: RPL19 has been identified among nine key proteins related to COVID-19 that are involved in STB regulation . This finding suggests common immunomodulatory mechanisms between different infectious diseases.

The proposed mechanism involves RPL19 suppressing B cells naive populations through downregulation of CD14 expression, potentially contributing to immune evasion by pathogens and disease progression . These relationships highlight the importance of understanding how ribosomal proteins like RPL19 may have extraribosomal functions in immune regulation during infectious diseases.

What is the significance of RPL19 as a prognostic biomarker in hepatocellular carcinoma?

RPL19 has emerged as a significant prognostic biomarker in hepatocellular carcinoma (HCC) with multiple lines of evidence supporting its clinical relevance:

• Differential expression: Tissue microarray analysis demonstrates that RPL19 is significantly overexpressed in HCC tumor tissues compared to non-tumor tissues (p = 0.016) .

• Survival correlation: High RPL19 expression strongly correlates with poor prognosis in HCC patients (p < 0.0007), suggesting its potential as a predictive biomarker for patient outcomes .

• Pathway alterations: Gene enrichment analysis reveals that RPL19 overexpression is associated with:

  • Upregulation of cell cycle pathways, potentially promoting tumor proliferation

  • Downregulation of bile acid metabolism pathways, which may affect liver function and homeostasis

• Immune microenvironment impact: High RPL19 expression correlates with suppression of immune response in the tumor microenvironment, potentially contributing to immune evasion mechanisms .

These findings collectively suggest that RPL19 may play an important role in promoting tumor progression in HCC, beyond its canonical ribosomal function. This positions RPL19 as a promising biomarker for HCC prognosis and potentially as a therapeutic target for precision medicine approaches.

How can researchers integrate RPL19 antibody-based detection with other molecular profiling approaches?

Integrating RPL19 antibody-based detection with other molecular profiling approaches can provide comprehensive insights into disease mechanisms. Here are methodological approaches for such integration:

• Multi-omics correlation studies:

  • Combine RPL19 protein expression data from antibody-based detection with transcriptomic data to identify potential post-transcriptional regulation

  • Correlate RPL19 expression with genomic alterations to identify potential genetic drivers of RPL19 dysregulation

  • Integrate RPL19 protein levels with metabolomic profiles, particularly focusing on pathways identified in previous research (e.g., bile acid metabolism in HCC )

• Single-cell multi-parameter analysis:

  • Employ single-cell technologies combining RPL19 antibody detection with other markers to characterize cellular heterogeneity

  • For example, combine RPL19 with CD14 and B cell markers in infectious disease contexts based on their established correlations

  • Use multiplexed imaging approaches like Imaging Mass Cytometry or CODEX for spatial relationship analysis

• Functional genomics integration:

  • Correlate RPL19 antibody-based detection with CRISPR screening outcomes to identify functional relationships

  • Combine with phosphoproteomic data to map RPL19's influence on signaling networks

  • Integrate with chromatin accessibility data to explore potential regulatory mechanisms

• Clinical data integration:

  • Develop multiparameter prognostic models combining RPL19 antibody-based detection with other biomarkers

  • Create risk stratification algorithms integrating RPL19 expression with clinical parameters

Example Workflow for Integrated Analysis:

• Quantify RPL19 protein expression using validated antibody-based methods

• Perform RNA-seq on the same samples to assess transcriptional profiles

• Conduct pathway enrichment analysis focusing on immune pathways and disease-specific mechanisms

• Correlate findings with clinical outcomes and other relevant biomarkers

• Validate key findings using orthogonal methods and larger cohorts

This integrated approach allows researchers to position RPL19 within broader molecular networks and enhances the translational potential of RPL19-focused research.

What are common technical challenges when using RPL19 antibody and how can they be resolved?

Researchers may encounter several technical challenges when using RPL19 antibody. Here are common issues and their solutions:

Western Blot Challenges:

• Multiple bands or non-specific binding

  • Solution: Optimize blocking conditions (try 5% BSA instead of milk)

  • Solution: Increase antibody dilution (e.g., from 1:500 to 1:1000)

  • Solution: Add 0.1% Tween-20 to antibody dilution buffer

  • Solution: Validate with positive control lysates (e.g., HeLa, MCF-7, or 293 cell lysates )

• Weak or no signal

  • Solution: Reduce antibody dilution (e.g., from 1:500 to 1:300)

  • Solution: Increase protein loading (30-50 μg)

  • Solution: Optimize antigen retrieval methods

  • Solution: Extend primary antibody incubation time (overnight at 4°C)

  • Solution: Use enhanced detection systems (e.g., high-sensitivity ECL substrates)

Immunohistochemistry/Immunofluorescence Challenges:

• High background

  • Solution: Extend blocking time (2 hours at room temperature)

  • Solution: Use additional blocking agents (e.g., add 0.1% cold fish skin gelatin)

  • Solution: Optimize secondary antibody dilution

  • Solution: Include additional washing steps

• Loss of antigenicity

  • Solution: Optimize fixation time (overfixation can mask epitopes)

  • Solution: Test different antigen retrieval methods (citrate pH 6.0, EDTA pH 8.0, enzymatic)

  • Solution: Store sections appropriately to prevent antigen degradation

Cross-Reactivity Issues:

• Unexpected cross-species reactivity

  • Solution: Validate antibody specifically for your species of interest

  • Solution: Consider species-specific antibodies if available

  • Solution: Include appropriate negative controls

• Non-specific binding to other ribosomal proteins

  • Solution: Perform peptide competition assays to confirm specificity

  • Solution: Use genetic approaches (siRNA knockdown) to validate specificity

  • Solution: Consider monoclonal antibodies for increased specificity

How can researchers validate RPL19 antibody performance in novel experimental contexts?

When applying RPL19 antibody to novel experimental contexts, thorough validation is essential to ensure reliable results. Here is a comprehensive validation strategy:

Step 1: Literature and Database Review

• Search for previous applications of RPL19 antibody in similar contexts

• Review protein atlas databases for expected expression patterns

• Identify potential confounding factors specific to your experimental system

Step 2: Positive and Negative Controls

• Positive controls: Include samples known to express RPL19 (e.g., HeLa cells )

• Negative controls:

  • Secondary antibody only controls

  • Isotype controls to assess non-specific binding

  • If possible, RPL19 knockdown/knockout samples

Step 3: Orthogonal Validation

• Compare protein detection with mRNA expression (RT-qPCR)

• Validate with alternative antibodies targeting different epitopes of RPL19

• Consider mass spectrometry validation for definitive protein identification

Step 4: Application-Specific Validation

• For Western blot: Confirm band at expected molecular weight (~23 kDa)

• For IHC/IF: Compare staining pattern with known subcellular localization

• For flow cytometry: Validate with fluorescence-minus-one (FMO) controls

Step 5: Titration and Optimization

• Perform antibody titration to determine optimal concentration

• Optimize critical protocol parameters (fixation, permeabilization, antigen retrieval)

• Test different detection systems for optimal signal-to-noise ratio